JAN 5 = 2006
I | L
510(k) Summary of Safety and Effectiveness
Chromolite™ System
510(k) Number K_05 3304
Applicant: Chromogenex Plc.
Address: Units 1 & 2 Heol Rhosyn
Parc Dafen
Llanelli
Carmarthenshire
S. Wales
SA14 8QG
UK
Contact Person: Mr. Chris Williams, Product Development Director
Telephone: +44 (0) 1554 755444
Fax: +44 (0) 1554 755333
Date prepared: July 2005
Device Trade Name: Chromolite™ System
Common Name: Intense Pulsed Light (IPL)
Classification Name: Laser Surgical Instrument 21 C.F.R § 878.4810.
Product Classification: Class II device.
Product Code: GEX
Legally Marketed Predicate The Chromolite™ System is substantially equivalent in terms of
Device: technological characteristics, performance, intended use,
indications for use and operator interface to;
« Orion lasers, Lovely system Il (Harmony) (KO033946)
System Description: The Chromolite™ is a Intense Pulsed Light-sased medical device
utilising xenon flashlamp technology to illuminate the dermis to
offer light based therapies as listed in the indications of use. The
Chromolite™ emits light at 390nm to 1200nm via a 50mm x 15mm
wavequide at a repetition rate of 0.5Hz.
Performance Standards: The device complies with the European Medical Directive
93/42/EEC concerming medica! devices, and will comply with
voluntary standards UL60601-1:1996 when marketed in the U.S
Chromotite™ 510(k) 510(k) Summary Section 2-14

SFY OD VDL
KO) y 824 ata
Indications for use: The Chromolite™ System is intended for use in aesthetic and
cosmetic applications requiring selective photothermolysis
photocoagulation or coagulation) and hemostasis of soft tissue in
the medical specialities of plastic surgery and dermatology as
follows:

« The treatment of moderate inflammatory acne vulgaris

« The treatment of benign pigmented epidermal lesions
including dyschromia, hyper-pigmentation, melasma,
ephelides (freckles)

e The treatment of cutaneous lesions including warts, scars,
and striae.

« The treatment of benign cutaneous vascular lesions,
including port wine stains, hemangiomas, facial, truncal
and leg telangiectasias, erythema of rosacea, angiomas,
and spider angiomas, poikiloderma of civatte, leg veins
and venous malformations.

¢ The removal of unwanted hair and to effect stable longterm or permanent hair reduction.

1 = Permanent hair reduction is defined as a long-term stable
reduction in the number of hairs re-growing after a treatment
regimen.

Conclusion: The Chromolite system is substantially equivalent to its predicate
device cited above, and raises no new safety and/or efficacy
issues.

Chromolite™ 540(k) 510(k) Summary Section 2-2

: Wa DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850
JAN 5 = 2006
Chromogenex Plc
c/o Mare M. Mouser
Underwriters Laboratories, Inc.
2600 N.W. Lake Road
Camas, Washington 98607
Re: K053324
Trade/Device Name: Chromolite System
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for usc in general and plastic surgery and in
dermatology
Regulatory Class: II
Product Code: GEX
Dated: December 21, 2005
Received: December 22, 2005
Dear Mr. Mouser:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug.
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (sce above) into either class II (Special Controls) or class II] (PMA). it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations. Title 21, Parts 800 to 898. In addition. FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1 050.

Page 2 - Marc M. Mouser
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification” (2 1CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http://www. fda.gov/cdrh/industry/support/ index.html.

Sincerely yours,

(s- Mark N. Melkerson
Acting Director
Division of General, Restorative
and Neurological Devices

Office of Device Evaluation

Center for Devices and Radiological Health
Enclosure

chromogenex’
| light technologies
een en LLC
Indications for Use
,

510(k) Number (if known): {( 05 3 pal
Device Name: Chromolite system.
indications for Use for Fitzpatrick skin types (I to V)

« The treatment of moderate inflammatory acne vulgaris

« The treatment of benign pigmented epidermal lesions including dyschromia,
hyperpigmentation, melasma, ephelides (freckles)

« The treatment of cutaneous lesions including warts, scars, and striae.

« The treatment of benign cutaneous vascular lesions, including port wine stains,
hemangiomas, facial, truncal and leg telangiectasias, erythema of rosacea,
angiomas, and spider angiomas, poikiloderma of civatte, leg veins and venous
malformations

«The removal of unwanted hair and to effect stable long-term or permanent hair
reduction.

1 = Permanent hair reduction is defined as a long-term stable reduction in the number of hairs
re-growing after a treatment regimen.
Prescription Use ___ x ANDIOR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF
NEEDED)
Concurrence of CDRH, Office of Device Evauation(ODE)—~S*~<“CS~S~*~“—sS*~*~“—s~S~s~CSs~S™SSSS
<—<_
a .
Page _1_ of _1__ Zz l ——_— >
(Division Sign-Off)
Division of General, Restorative,
and Neurological Devices 4
510(k) Number_053224
Chromolite 510(k} application Indications for use Section: 5-3

